An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose ofBAY 1251152 in patients with advanced cancer

Protocol: 
AAAQ4758
Phase: 
I

An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose ofBAY 1251152 in patients with advanced cancer

The purpose of the study is to evaluate the safety and tolerability of BAY 1251152 in patients with any type of solid tumors or non-indolent non-hodgkins lymphoma. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment.

Are you Eligible? (Inclusion Criteria)

1. Patients must have advanced solid tumors or non-indolent non Hodgkins lymphoma
2. Patients must have exhausted all standard treatments for their disease
3. Patients must have adequate organ and bone marrow function
4. Patients must have recovered from all prior cancer therapy side effects

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States